Entera Bio (ENTX) Cash from Financing Activities (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Cash from Financing Activities of $130000.0 in Q1 2026, down 25.29% on a QoQ basis from $174000.0 in Q4 2025, and down 99.03% year-over-year from $13.3 million in Q1 2025.
Entera Bio (ENTX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $130000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 99.03% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $503000.0 (down 97.17% YoY) and the FY2025 annual result came in at $13.7 million, up 206.3% from the prior year.
- Cash from Financing Activities retreated to $130000.0 in Q1 2026, from $174000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $13.3 million in Q1 2025 and troughed at -$51000.0 in Q2 2025.
- A 5-year average of $2.0 million and a median of $152000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Biggest YoY gain for Cash from Financing Activities was 44356.67% in 2025; the steepest drop was 104.19% in 2025.
- Tracing ENTX's Cash from Financing Activities over 5 years: stood at $13000.0 in 2022, then soared by 46292.31% to $6.0 million in 2023, then sank by 46.66% to $3.2 million in 2024, then tumbled by 94.59% to $174000.0 in 2025, then fell by 25.29% to $130000.0 in 2026.
- Business Quant data shows ENTX's Cash from Financing Activities at $130000.0 in Q1 2026, $174000.0 in Q4 2025, and $250000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Entera Bio | 57.79 Mn | 53.65 Mn | - | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 13.34 Mn |
| Mar 31, 2025 | 13.34 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 13,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 6.03 Mn |
| Dec 31, 2023 | 6.03 Mn |